CLVT vs. RTO, CART, ALLE, FTAI, MEDP, ULS, WPP, GLOB, HQY, and STN
Should you be buying Clarivate stock or one of its competitors? The main competitors of Clarivate include Rentokil Initial (RTO), Maplebear (CART), Allegion (ALLE), FTAI Aviation (FTAI), Medpace (MEDP), UL Solutions (ULS), WPP (WPP), Globant (GLOB), HealthEquity (HQY), and Stantec (STN). These companies are all part of the "business services" industry.
Clarivate vs.
Clarivate (NYSE:CLVT) and Rentokil Initial (NYSE:RTO) are both computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, community ranking, dividends and analyst recommendations.
Clarivate received 44 more outperform votes than Rentokil Initial when rated by MarketBeat users. Likewise, 53.93% of users gave Clarivate an outperform vote while only 30.77% of users gave Rentokil Initial an outperform vote.
Rentokil Initial has higher revenue and earnings than Clarivate.
Rentokil Initial has a net margin of 0.00% compared to Clarivate's net margin of -50.00%. Clarivate's return on equity of 9.69% beat Rentokil Initial's return on equity.
85.7% of Clarivate shares are held by institutional investors. Comparatively, 9.9% of Rentokil Initial shares are held by institutional investors. 23.1% of Clarivate shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Rentokil Initial had 18 more articles in the media than Clarivate. MarketBeat recorded 26 mentions for Rentokil Initial and 8 mentions for Clarivate. Clarivate's average media sentiment score of 0.90 beat Rentokil Initial's score of 0.02 indicating that Clarivate is being referred to more favorably in the media.
Clarivate has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Rentokil Initial has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.
Clarivate currently has a consensus target price of $7.10, indicating a potential upside of 30.16%. Rentokil Initial has a consensus target price of $29.00, indicating a potential upside of 21.95%. Given Clarivate's higher probable upside, equities analysts clearly believe Clarivate is more favorable than Rentokil Initial.
Summary
Clarivate beats Rentokil Initial on 10 of the 17 factors compared between the two stocks.
Get Clarivate News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLVT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Clarivate Competitors List
Related Companies and Tools
This page (NYSE:CLVT) was last updated on 1/22/2025 by MarketBeat.com Staff